Immunomodulatory Effects in a Phase II Study of Lenalidomide Combined with Cetuximab in Refractory KRAS-Mutant Metastatic Colorectal Cancer Patients

This study assessed the immunomodulatory effects in previously treated KRAS-mutant metastatic colorectal cancer patients participating in a phase II multicenter, open-label clinical trial receiving lenalidomide alone or lenalidomide plus cetuximab. The main findings show the T cell immunostimulatory...

Descripción completa

Detalles Bibliográficos
Autores principales: Gandhi, Anita K., Shi, Tao, Li, Mingyu, Jungnelius, Ulf, Romano, Alfredo, Tabernero, Josep, Siena, Salvatore, Schafer, Peter H., Chopra, Rajesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3823649/
https://www.ncbi.nlm.nih.gov/pubmed/24244687
http://dx.doi.org/10.1371/journal.pone.0080437

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3823649/
https://www.ncbi.nlm.nih.gov/pubmed/24244687
http://dx.doi.org/10.1371/journal.pone.0080437

Ejemplares similares